Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Virus|
|Published species reactivity||Virus, Human|
|Host / Isotype||Mouse / IgG2a, kappa|
|Immunogen||Recombinant HPV-16 E7 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 2 publications below|
MA5-14132 targets Human Papilloma Virus Type 16-E7 (HPV 16-E7) in FACS and IF applications and shows reactivity with Virus samples.
The MA5-14132 immunogen is recombinant HPV-16 E7 protein.
E7 is an early protein of type 16 human papilloma virus (HPV 16-E7). Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. HPV types 6 and 11 have been associated with relatively benign diseases such as genital warts but types 16 and 18 are strongly associated with cervical, vaginal, and vulvar malignancies.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The presence of human papillomavirus 16 in neural structures and vascular endothelial cells.
MA5-14132 was used in immunohistochemistry to investigate the location of HPV 16 genetic materialls in neurons and vascular endothelium
|Füle T,Máthé M,Suba Z,Csapó Z,Szarvas T,Tátrai P,Paku S,Kovalszky I||Virology (348:289)||2006|
Decreased expression of human papillomavirus E2 protein and transforming growth factor-beta1 in human cervical neoplasia as an early marker in carcinogenesis.
MA5-14132 was used in immunohistochemistry to study the roles of HPV and TGF-beta1 during cervical tumorigenesis
|Torng PL,Chan WY,Lin CT,Huang SC||Journal of surgical oncology (84:17)||2003|